SCHEMBL2693341

SCHEMBL2693341

Cc1ccc(C(=O)N2CC[C@@H](O)[C@H]2C(=O)NO)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
TP53 P04637 2/20 0.49
TSHR P16473 3/20 0.40
KMT2A Q03164 2/20 0.40
HSD11B1 P28845 1/20 0.39
RAB9A P51151 1/20 0.39
CNR2 P34972 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 2/20 0.37
GPR183 P32249 1/20 0.37
GAA P10253 2/20 0.36
MMP13 P45452 3/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
MMP8 P22894 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
PDK2 Q15119 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1909511 0.80 MMP3 (0.50) HPGDTSHRSMN1; SMN2GAAMMP13
SCHEMBL2692903 0.77 MMP13 (0.43) ALDH1A1SMN1; SMN2MMP13MMP2MMP9
SCHEMBL202818 0.77 MMP13 (0.43) ALDH1A1SMN1; SMN2MMP13MMP2MMP9
SCHEMBL2693072 0.75 MMP13 (0.45) MMP13MMP2MMP9MMP8
SCHEMBL203227 0.74 MMP13 (0.47) HSD11B1MMP13MMP2MMP9
SCHEMBL9903924 0.74 MMP13 (0.47) HSD11B1MMP13MMP2MMP9
SCHEMBL2692091 0.74 MMP13 (0.47) HSD11B1MMP13MMP2MMP9
SCHEMBL4650506 0.74 PDK2 (0.39) ALDH1A1TSHRKMT2AHSD11B1PDK2
SCHEMBL4650510 0.74 PDK2 (0.39) ALDH1A1TSHRKMT2AHSD11B1PDK2
SCHEMBL201209 0.74 PDK2 (0.39) ALDH1A1TSHRKMT2AHSD11B1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 ALDH1A1 343/4885HPGD 19/4885TP53 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.